Effect of Onset-to-Admission Time and Care Bundle Achievement on Functional Outcomes in Patients With ICH A Population-Based Study


Por: Lambea-Gil Á, Marti-Fabregas J, Cardona P, Rodriguez-Luna D, Millán M, Amaro S, Prats-Sanchez L, Silva Y, Seró L, Rodriguez-Campello A, Cánovas D, Martinez-Domeño A, Guasch-Jiménez M, Ezcurra-Díaz G, Carcel-Marquez J, Fernandez-Cadenas I, Pérez De La Ossa N, Abilleira S, Salvat-Plana M, Fagundez O, Camps-Renom P and Ramos-Pachón A

Publicada: 21 oct 2025 Ahead of Print: 30 sep 2025
Resumen:
Background and Objectives Intracerebral hemorrhage (ICH) remains a leading cause of morbidity and mortality, with limited effective treatments. Early implementation of a care bundle protocol (CBP) within 6 hours of symptom onset has been shown to improve functional outcomes, although its effect beyond this time frame remains unclear. We assessed the impact of onset-to-admission (OTA) time and CBP achievement on functional outcome and mortality in patients with acute spontaneous ICH. Methods We conducted a population-based study of a prospective cohort of consecutive patients diagnosed with acute spontaneous ICH between 2020 and 2022 in Catalonia, Spain. Inclusion criteria were patients aged 18 years or older, OTA time <24 hours, and a baseline modified Rankin Scale (mRS) score <= 3. CBP achievement was defined as attaining control in the first 24 hours of blood pressure (<140/90 mm Hg), glycemia (<150 mg/dL), body temperature (<37.5 degrees C), and blood oxygen saturation (>92%) and, if required, anticoagulation reversal. The primary outcome was the proportion of patients with a favorable functional outcome, defined as mRS score <= 3 at 3-month follow-up. The effects of OTA time and CBP achievement on outcomes were evaluated using multivariable logistic regression. Potential interaction between OTA time and CBP achievement was assessed using the likelihood ratio test. Results A total of 1,821 patients were included (mean age 70.3 +/- 14.1 years, 37.7% women). CBP was achieved in 27.7% of patients. Shorter OTA time was independently associated with poorer functional outcome (adjusted odds ratio [aOR](x1h) 1.04, 95% CI 1.02-1.06). CBP achievement was associated with a higher probability of favorable outcome at 3 months (aOR 1.66, 95% CI 1.29-2.15). An interaction between OTA time and CBP achievement was observed (p = 0.016), indicating greater CBP benefits for earlier admission. This interaction was evident up to 13.8 hours after symptom onset, with the CBP benefit concentrated in the first 8 hours. Discussion Our findings highlight the importance of timely CBP application to improve functional outcome in patients with ICH, even beyond the first 6 hours after symptom onset. While earlier intervention remains ideal, our results support expanding CBP implementation and promoting "Code ICH" initiatives to enhance patient outcomes in stroke care systems.

Filiaciones:
Lambea-Gil Á:
 Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

 Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain

 Department of Medicine, Universitat Autònoma de Barcelona, Spain

Marti-Fabregas J:
 Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

 Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain

 Department of Medicine, Universitat Autònoma de Barcelona, Spain

Cardona P:
 Stroke Unit, Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain

Rodriguez-Luna D:
 Stroke Unit, Department of Neurology, Hospital Universitari Vall d'Hebron, Barcelona, Spain

 Stroke Research Group, Vall d'Hebron Research Institute, Barcelona, Spain

:
 Neurology Service, Neurosciences Department, Hospital Germans Trias i Pujol, Badalona, Spain

 Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain

Amaro S:
 Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic de Barcelona, Spain

 Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain

Prats-Sanchez L:
 Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

 Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain

Silva Y:
 Department of Neurology, Hospital Universitari Dr. Josep Trueta, Girona, Spain

 Department of Medicine, Universitat de Girona, Spain

 Cerebrovascular Pathology Group, IDIBGI, Girona, Spain

Seró L:
 Stroke Unit, Department of Neurology, Hospital Universitari Joan XXIII de Tarragona, Spain

Rodriguez-Campello A:
 Stroke Unit, Department of Neurology, Hospital Del Mar, Barcelona, Spain

Cánovas D:
 Stroke Unit, Department of Neurology, Hospital Universitari Parc Taulí, Sabadell, Spain

Martinez-Domeño A:
 Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

 Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain

Guasch-Jiménez M:
 Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

 Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain

Ezcurra-Díaz G:
 Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

 Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain

Carcel-Marquez J:
 Stroke Pharmacogenomics and Genetics Research Group, Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain

Fernandez-Cadenas I:
 Stroke Pharmacogenomics and Genetics Research Group, Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain

:
 Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

 Neurology Service, Neurosciences Department, Hospital Germans Trias i Pujol, Badalona, Spain

 Stroke Programme, Health Department of Catalonia, Barcelona, Spain

Abilleira S:
 Stroke Programme, Health Department of Catalonia, Barcelona, Spain

Salvat-Plana M:
 Stroke Programme, Health Department of Catalonia, Barcelona, Spain

 Agency for Health Quality and Assessment of Catalonia (AQUAS), Barcelona, Spain

 and

 CIBER Epidemiology and Public Health, Barcelona, Spain

Fagundez O:
 Neurology Service, Neurosciences Department, Hospital Germans Trias i Pujol, Badalona, Spain

 Agency for Health Quality and Assessment of Catalonia (AQUAS), Barcelona, Spain

 and

Camps-Renom P:
 Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

 Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain

Ramos-Pachón A:
 Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

 Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain

 Department of Medicine, Universitat Autònoma de Barcelona, Spain
ISSN: 00283878





Neurology
Editorial
Lippincott Williams & Wilkins Ltd., TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 105 Número: 8
Páginas:
WOS Id: 001758230300001
ID de PubMed: 41026995

MÉTRICAS